- ALT-B4-based subcutaneous ADC administration demonstrated potential for faster drug absorption, improved injection-site tolerability, and reduced systemic adverse effects.

- Combining the next-generation ADC market with the convenience of subcutaneous administration could offer a solution for developing effective ADC therapies.

DAEJEON, South Korea, Oct.26, 2026 - Alteogen Inc. (KOSDAQ:196170), a biopharmaceutical platform company led by CEO Tae-Yon Chun, announced on the 26th that it had presented a poster at the European Society for Medical Oncology’s annual meeting, ESMO Congress 2026, held in Madrid, Spain. The poster presented research findings on converting antibody-drug conjugate (ADC) therapies to subcutaneous (SC) administration using ALT-B4.

ADCs are next-generation cancer therapies designed to selectively target cancer cells by attaching potent anticancer drugs to antibodies that recognize cancer-specific targets. Given their high therapeutic potential, ADCs are attracting considerable attention as next-generation cancer treatments. The market, valued at approximately USD 12 billion in 2024, is projected to grow significantly, reaching USD 57 billion by 2032.

However, because ADCs contain highly potent anticancer agents, managing adverse effects remains critical. Reducing the treatment burden associated with intravenous administration is another important challenge. Alteogen has focused on the potential of ADCs administered subcutaneously using ALT-B4 (generic name: berahyaluronidase alfa) to mitigate the rapid increase in blood drug concentrations observed following IV administration while maintaining bioavailability. These characteristics could enable sufficient drug delivery while reducing systemic toxicity associated with transiently elevated drug concentrations. Alteogen has conducted research to investigate this potential.

In this study, Alteogen evaluated drug absorption, tolerability, and safety in animal models using its proprietary HER2-targeting ADC, ALT-P7, formulated for subcutaneous administration with ALT-B4, a recombinant human hyaluronidase.

The results showed that ALT-B4 enhanced ADC absorption in a dose-dependent manner and achieved bioavailability comparable to that of IV administration. In addition, co-administration with ALT-B4 enabled more uniform distribution of the drug within the epidermis, resulting in reduced skin damage at the injection site.

The study also identified the potential to reduce systemic adverse effects associated with ADC therapy. IV administration of the ADC was associated with increased neutropenia and hepatotoxicity, whereas subcutaneous administration in combination with ALT-B4 reduced these adverse effects, indicating potential improvements in hematologic safety. The subcutaneously administered ADC also exhibited a lower maximum plasma concentration (Cmax) than the intravenously administered formulation, suggesting the potential to reduce systemic toxicity and related adverse effects.

At ESMO Congress 2026, Alteogen plans to share these findings with European and global oncology experts and continue discussions on the development of subcutaneous ADC therapies.

“ADCs are attracting attention as next-generation cancer therapies, and global pharmaceutical companies are actively developing treatments in this field. While our partner is advancing the clinical development of subcutaneous ADC formulation using ALT-B4, this study is significant in that it demonstrates the potential to improve both administration convenience and safety,” said Tae-Yon Chun, Ph.D., CEO of Alteogen.  “Through global academic conferences, we will continue to actively communicate the differentiated advantages and development potential that ALT-B4 can offer in the ADC field.”

Meanwhile, ALT-B4 is a recombinant human hyaluronidase used to convert biologic drugs administered intravenously into subcutaneous formulations. In 2024, Alteogen signed a licensing agreement with Daiichi Sankyo for the development of the world’s first subcutaneous ADC therapy, further expanding the application of its platform technology.

Alteogen presented research findings in a poster presentation at ESMO 2026, held in Madrid, Spain

About Alteogen
Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as antibody-drug conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP^® and NexMab^® platform technologies, respectively. The company also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme^® technology, which enables the large-volume subcutaneous administration of drugs typically given as IV infusions. Alteogen was founded in 2008 and is listed on KOSDAQ (196170.KQ).

Media Contact: 
Investor Relations and Corporate Communications
E-mail:   ir@alteogen.com

Business Development
E-mail:   alliance@alteogen.com